Unicycive therapeutics.

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Unicycive therapeutics. Things To Know About Unicycive therapeutics.

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate).作者:Wenjing 微信公众号:蹊之美股生物医药 / CaesarBiotech 标的公司: Unicycive Therapeutics, Inc(NASDAQ:UNCY) Unicycive Therapeutics是一家生物科技公司,成立于2016年,专注于肾病治疗。目前有两个管线,UNI 218(Renazorb)指征慢性肾病患者的高磷酸盐血症,UNI494指征...Unicycive Interview with CEOCFO Magazine . rss_feed RSS . Email Alerts; Contacts; RSS News FeedMar 8, 2023 · Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.As of March 9, 2023, the average one-year price target for Unicycive Therapeutics is $9.56. The forecasts range from a low of $3.03 to a high of $14.18. The average price target represents an ...

The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeutic and appreciative.

Oxylanthanum Carbonate (OLC) - Unicycive. Oxylanthanum Carbonate (OLC) is an unapproved investigational new drug being developed under FDA’s 505 (b) (2) regulatory procedure. If approved, OLC will share substantially the same product label and prescribing information as the reference-listed drug Fosrenol® (lanthanum carbonate), with the ... Investors - Unicycive. [WE DO NOT CONTROL THIS SECTION OF THE SITE. WE WILL CONNECT WITH THE THIRD PARTY BUT MAY NEED TO CREATE THE HEADER IMAGE. THIS COULD BE A MAGNIFYING GLASS MADE OUT OF DOTS.] [WE DO NOT CONTROL THIS SECTION OF THE SITE.Dec 1, 2023 · Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. Stock analysis for Unicycive Therapeutics Inc (UNCY:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.About Unicycive Therapeutics. Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using proprietary ...

Prelude Therapeutics is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, small molecule therapies that precisely target the key drivers of cancer cell growth and resistance. With our core competencies in cancer biology, medicinal chemistry, and drug development, we are rapidly translating our …

LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...

Feb 2, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Find the latest Unicycive Therapeutics, Inc. (UNCY) stock quote, history, news and other vital information to help you with your stock trading and investing. Unicycive Therapeutics, Inc. 4300 El Camino Real Suite 210 Los Altos, CA 94022 United States 650 351 4495 https://unicycive.com Sector(s) : Healthcare Industry : Biotechnology Full Time Employees : 12December 2023 Corporate Presentation (Unicycive Therapeutics Inc) Posted 2023-12-02, Public Technologies Headlines ) The text version of this document is not available. You can access the original document here. ... 2021 (Defence Therapeutics Inc) Public Technologies 2023-12-04, 20:51. Management Discussion and Analysis for the Six …It’s how we each promise to be at Alterome. In fact, all of us sign a co-elevation contract. We started a Movement at Alterome to build an amazing company where people value each other and work together, with one mission in mind…To discover precise therapies and inspire hope for individuals affected by cancer. Our focus is on the patients.

Jun 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational ... About Unicycive . Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead product candidate, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...29 Mar 2022 ... No photo description available. New York Stock Exchange. New York Stock Exc...Mar 6, 2023 · Item 1.01. Entry into a Material Definitive Agreement. On March 3, 2023, Unicycive Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (the "Investors"), pursuant to which the Company agreed to issue and sell, in a private placement (the "Offering"), 30,190 shares of Series A-1 Convertible Preferred Stock ... Unicycive Therapeutics Inc (NASDAQ: UNCY) shares are exploding higher Monday after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch ...Unicycive Therapeutics Inc UNCY is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and their ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...

Jul 20, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Unicycive Interview with CEOCFO Magazine . rss_feed RSS . Email Alerts; Contacts; RSS News FeedNov 30, 2023 · Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Unicycive Therapeutics has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Previous Next UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com. Investor Contact: [email protected] (650) 900-5470. Anne Marie Stern Investor Relations [email protected] 212-362-1200. SOURCE: Unicycive Therapeutics, Inc ...Nov 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... Unicycive Therapeutics Rebounds and Closes Up 17%. By Luisa Beltran. Updated July 13, 2021, 6:24 pm EDT / Original July 13, 2021, 10:36 am EDT. Share. Resize. Reprints.

Unicycive Therapeutics, Inc. employs a comprehensive promotion strategy that integrates the details of its products, pricing, and placement. The company carefully constructs its promotional message to convey the unique value proposition of its therapies to potential consumers. This message is designed to educate and persuade individuals about ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on …

UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com. Investor Contact: [email protected] (650) 900-5470. Anne Marie Stern Investor Relations [email protected] 212-362-1200. SOURCE: Unicycive Therapeutics, Inc ...Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with ...Oct 23, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... Inside Unicycive Therapeutics, Inc.'s 10-K Annual Report: Financial - Expense Highlight. These situations, or others associated with COVID-19, could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material adverse effect on our business and financial condition. Financial - Expense …Oct 23, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ... Pharmaceutical and Business Operations, Unicycive Therapeutics, Inc., Los Altos, California, USA. PMID: 37231835; PMCID: PMC10614253; DOI: 10.1159/000530989 ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Aarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...UNICYCIVE THERAPEUTICS, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN . Section 1. Purpose of Plan. The name of the Plan is the Unicycive Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan. The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, independent contractors and consultants of …Legal Name Unicycive Therapeutics, Inc. Stock Symbol NASDAQ:UNCY. Company Type For Profit. Phone Number (650) 384-0642. Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the ...

As of March 9, 2023, the average one-year price target for Unicycive Therapeutics is $9.56. The forecasts range from a low of $3.03 to a high of $14.18. The average price target represents an ...Unicycive Therapeutics, Inc. $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with …About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Instagram:https://instagram. northern oil and gas stock pricebest japan etfsauntozonevanguard vbtlx Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a … high yeild etfshome investment companies Unicycive Therapeutics. stock was originally listed at a price of $5.85 in Jul 13, 2021. If you had invested in Unicycive Therapeutics stock at $5.85, your return over the last 2 years would have been -91.4%, for an annualized return of -70.68% (not including any dividends or dividend reinvestments). pubmatic inc. In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...Get the latest Unicycive Therapeutics Inc (UNCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.